Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses

被引:4
|
作者
Xie, Feng [1 ,2 ,5 ]
Zhou, Ting [1 ,3 ]
Humphries, Brittany [1 ]
Neumann, Peter J. [4 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[2] McMaster Univ, Fac Hlth Sci, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[3] China Pharmaceut Univ, Ctr Pharmacoecon & Outcome Res, Nanjing, Peoples R China
[4] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 1280 Main St West, Hamilton, ON L8S 4L8, Canada
关键词
age; cost-effectiveness analysis; elderly; discrimination; quality-adjusted life-year;
D O I
10.1016/j.jval.2024.03.011
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Critics of quality-adjusted life-years argue that it discriminates against older individuals. However, little empirical evidence has been produced to inform this debate. This study aimed to compare published cost-effectiveness analyses (CEAs) on patients aged >= 65 years and those aged <65 years. Methods: We used the Tufts Cost-Effectiveness Analysis Registry to identify CEAs published in MEDLINE between 1976 and 2021. Eligible CEAs were categorized according to age (>= 65 years vs <65 years). The distributions of incremental cost-effectiveness ratios (ICERs) were compared between the age groups. We used logistic regression to assess the association between age groups and the cost-effectiveness conclusion adjusted for confounding factors. We conducted sensitivity analyses to explore the impact of mixed age and age-unknown groups and all ICERs from the same CEAs. Subgroup analyses were also conducted. Results: A total of 4445 CEAs categorized according to age <65 years (n = 3784) and age >= 65 years (n = 661) were included in the primary analysis. The distributions of ICERs and the likelihood of concluding that the intervention was cost-effective were similar between the 2 age groups. Adjusted odds ratios ranged from 1.132 (95% CI 0.930-1.377) to 1.248 (95% CI 0.970-1.606) (odds ratio >1 indicating that CEAs for age >= 65 years were more likely to conclude the intervention was cost-effective than those for age <65 years). Sensitivity and subgroup analyses found similar results. Conclusion: Our analysis found no systematic differences in published ICERs using quality-adjusted life-years between CEAs for individuals aged >= 65 years and those for individuals aged <65 years.
引用
收藏
页码:706 / 712
页数:7
相关论文
共 50 条
  • [31] Quality-adjusted life-years lack quality in pediatric care: A critical review of published cost-utility studies in child health
    Griebsch, I
    Coast, J
    Brown, J
    PEDIATRICS, 2005, 115 (05) : E600 - E614
  • [32] Quality-adjusted survival and cost-effectiveness of transmyocardial revascularization using the CO2 laser
    Gray, DT
    Walters, S
    Spertus, J
    Brazier, J
    Horvath, K
    CIRCULATION, 2005, 111 (20) : E319 - E319
  • [33] How Many Quality-Adjusted Life Years Do Patients Operated for CSM Gain?
    Englander, Zachary K.
    Chan, Andrew Kai-Hong
    Yang, Eunice
    Ambati, Vardhaan Sai
    Mummaneni, Praveen V.
    Bisson, Erica Fay
    Bydon, Mohamad
    Asher, Anthony L.
    Coric, Domagoj
    Kim, Paul Keetae
    NEUROSURGERY, 2025, 71 : 142 - 142
  • [34] Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review
    Gunda, Resign
    Chimbari, Moses John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [35] Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review
    Resign Gunda
    Moses John Chimbari
    Cost Effectiveness and Resource Allocation, 15
  • [36] Quality-adjusted life-years and other health indices: A comparative analysis
    McAlearney, AS
    Schweikhart, SB
    Pathak, DS
    CLINICAL THERAPEUTICS, 1999, 21 (09) : 1605 - 1629
  • [37] Cost-effectiveness of prostate cancer chemoprevention - A quality of life-years analysis
    Svatek, Robert S.
    Lee, J. Jack
    Roehrborn, Claus G.
    Lippman, Scoff M.
    Lotan, Yair
    CANCER, 2008, 112 (05) : 1058 - 1065
  • [38] Cost Effectiveness, Quality-Adjusted Life-Years and Supportive CareRecombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia
    Pierre-Yves Cremieux
    Stan N. Finkelstein
    Ernst R. Berndt
    Jeffrey Crawford
    Mitchell B. Slavin
    PharmacoEconomics, 1999, 16 : 459 - 472
  • [39] Quality-Adjusted Life-Years, Comparative Effectiveness in Cancer Care, and Measuring Outcomes in the Underserved
    Kilbridge, Kerry L.
    ONCOLOGY-NEW YORK, 2010, 24 (06): : 530 - 536
  • [40] QUALITY-ADJUSTED LIFE-YEARS FOR THE ESTIMATION OF EFFECTIVENESS OF SCREENING PROGRAMS: A SYSTEMATIC LITERATURE REVIEW
    Maklin, Suvi
    Rasanen, Pirjo
    Laitinen, Riikka
    Kovanen, Niina
    Autti-Ramo, Ilona
    Sintonen, Harri
    Roine, Risto P.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (02) : 145 - 151